Análisis Argos
MCK
MCKEn su precio1 señal de riesgo
McKesson Corporation · Healthcare
US$ 889.50
precio al 2026-07-28
Valor justo Argos*
US$ 730–909
vs. su valor justo
9% por encima
Score Argos
67/100
En su precio
LA RESPUESTA
El precio asume un crecimiento (11.9%) en línea con lo que la empresa demuestra (12.9%). Ni ganga ni exceso — el mercado le puso un precio razonable.
Recompensas
✓Cotiza 20% por debajo de su valor justo.
✓Las ganancias crecieron 45% el último año.
✓Retorno sobre el capital alto (215%).
Riesgos
!Venta significativa de insiders en el último trimestre.
!Altman Z'' en zona roja (0.6)
VALOR3/6FUTURO3/6PASADO5/6SALUD4/6DIVIDENDO4/6
El Iris de calidad
VALOR3/6FUTURO3/6PASADO5/6SALUD4/6DIVIDENDO4/6
ValorCerca de su valor justo
FuturoCrecimiento moderado
PasadoFundamentales sólidos y sostenidos
SaludBalance fuerte, deuda controlada
DividendoDevuelve capital al accionista
Score Argos67de 100En su precio
Ingresos▲12%
US$ 403.4 B
Margen operativo▲33%
1.6%
Flujo de caja libre▲9%
US$ 5.7 B
Deuda neta
US$ 4.6 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 104.1B
P/E21.9x
EV/EBITDA15.1x
FCF yield5.5%
ROIC215.1%
Margen operativo1.6%
Crecim. ingresos+12.4%/año
Piotroski F7/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

zacks.com · 9 jul
Brokers Suggest Investing in McKesson (MCK): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
zacks.com · 8 jul
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
zacks.com · 7 jul
McKesson (MCK) Increases Despite Market Slip: Here's What You Need to Know
McKesson (MCK) closed the most recent trading day at $807.33, moving +2.95% from the previous trading session.
zacks.com · 6 jul
Will McKesson (MCK) Beat Estimates Again in Its Next Earnings Report?
McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
fool.com · 6 jul
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.
seekingalpha.com · 4 jul
McKesson: The Healthcare Supplier On My Buy List This Summer, As Growth Accelerates
McKesson (MCK) is rated a buy, offering capital growth and dividend potential, underpinned by robust top-line and EPS growth. MCK's diversified portfolio, role in oncology and collaboration with big pharma names like AbbVie, and investment-grade Fitch rating support its investment case despite negative equity. Valuation appears compelling, with MCK trading at a forward earnings multiple of ~18x and estimated 18–22% upside by March 2028.
zacks.com · 2 jul
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
McKesson's growth in specialty pharma, oncology services and tech-driven solutions is boosting earnings, but policy and execution risks remain in focus.
zacks.com · 2 jul
Here's Why McKesson (MCK) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.